MarketLens

What is Krazati, and Where Does it Stand Today

6 months ago

SHARE THIS ON:

Exclusive Content for Pro Members

Pro members only. Upgrade to access this article, premium analysis, and stock recommendations.

Already a Pro member? Log in

SHARE THIS ON:

Why is the Low-Code Automation Market Exploding, and Where Does Appian Fit In

6 months ago

The Fed Has Pivoted: Where Should Investors Position for 2026?

10 months ago

Why is Roku's Stock Up Today, and What's Driving the Rally

7 months ago

What is Seagate Technology Holdings and Why Does it Matter Now

5 months ago

Iovance Reports Updated IOV-LUN-202 Results and Adds Precision TIL Strategy for Second-Line Metastatic Non-Small-Cell Lung Cancer (mNSCLC)

Iovance reported a 24.6% ORR in 69 non-squamous mNSCLC patients, consistent with prior results, and plans a 2027 sBLA for lifileucel. KRAS wild-type achieved 43.3% ORR versus 11.4% in KRAS-mutant dise...

TIL

Stock News•3 months ago

Lilly's olomorasib receives U.S. FDA's Breakthrough Therapy designation for the treatment of previously treated KRAS G12C-mutant advanced pancreatic cancer

Eli Lilly's olomorasib received FDA Breakthrough Therapy designation for previously treated KRAS G12C-mutant advanced pancreatic cancer, after showing potential as a next-generation inhibitor. The des...

LLY

Stock News•3 months ago

Kura Oncology: A Menin Inhibitor Launch With More Than One Way To Win

Kura Oncology positions ziftomenib as an AML combination backbone, supported by high remission rates and tolerability data. A robust cash position from Kyowa Kirin payments funds the pivotal KOMET-017...

KURA